Amivas` Artesunate Amivas (artesunate) Receives Approval in Europe
AMIVAS Ireland Ltd., specialists in treatments for rare and neglected tropical diseases, including severe malaria, announced today the Medicines &...
Enforcement Report - Week of October 13, 2021
WHO-led trial to study three anti-inflammatory drugs for COVID-19 patients
After months in the doldrums, one of the world’s largest trials of COVID-19 treatments is finally restarting. Solidarity, a global study led by the World Health Organization (WHO), will test three new drugs in hospitalized COVID-19 patients: the cancer drug imatinib, an antibody named infliximab that is used to treat autoimmune diseases, and artesunate, an antimalarial.
La Jolla Pharmaceutical Company was granted an Orphan Drug Designation from the FDA for the Investigational Drug Product, LJPC-0118 (artesunate), for the treatment of malaria. LJPC-0118, artesunate, demonstrated to be superior to quinine in reducing mortality in patients with falciparum malaria infection
Drug major CiplaBSE 0.65 % in partnership with Medicines for Malaria Venture (MMV) today launched a drug used for the treatment of severe malaria in young children.
Attix Pharmaceuticals Recalls Hundreds of APIs From the U.S.